Parathyroid Hormone Analogues
5 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- AbaloparatideAbaloparatide is a prescription, subcutaneously administered analogue of parathyroid hormone‑related protein (PTHrP) approved for the treatment of osteoporosis. It belongs to the class of bone‑forming (anabolic) agents and is recommended for individuals at very high risk of fracture, such as those with recent vertebral fractures or low bone mineral density.
- Ostabolin-COstabolin‑C (also called PTH(1‑31) cyclic lactam or RS‑66271) is an investigational cyclic fragment of human parathyroid hormone. It is being studied primarily for its ability to stimulate bone formation in osteoporosis and, experimentally, to enhance bone‑marrow recovery after chemotherapy or radiation. The peptide is administered by subcutaneous injection and remains in the research‑only category pending further clinical evaluation.
- PalopegteriparatidePalopegteriparatide (brand name Yorvipath, also called TransCon PTH) is a prescription, subcutaneously administered, long‑acting analog of parathyroid hormone (PTH 1‑34) approved for treatment of adults with hypoparathyroidism. By replacing the missing hormone, it aims to normalize serum calcium, reduce dependence on oral calcium and active vitamin D, and improve related symptoms and quality of life.
- Parathyroid Hormone-Related Protein 1-36Parathyroid hormone‑related protein 1‑36 (PTHrP (1‑36)) is a synthetic peptide that mimics the N‑terminal region of the endogenous hormone‑like factor PTHrP. It binds the same type‑1 parathyroid hormone receptor (PTH1R) as parathyroid hormone, activating cAMP signaling. Early human studies have examined intermittent subcutaneous dosing as an anabolic stimulus for bone in postmenopausal osteoporosis and as a diagnostic probe for calcium‑phosphate disorders. The compound remains investigational and is not approved for therapeutic use.
- TeriparatideTeriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34) administered by daily subcutaneous injection to treat postmenopausal osteoporosis. It stimulates new bone formation, raising bone‑mineral density (BMD) at the spine and hip and lowering the risk of vertebral fractures, especially in patients who have not previously used bisphosphonates.